ClinicalTrials.gg
Not yet recruitingNCT07099495Updated Aug 1, 2025

REDUCED FUNCTIONALITY AND KINESIOPHOBIA IN PATIENTS WITH HEART FAILURE: USE OF ALTERNATIVE THERAPEUTIC STRATEGIES

An interventional study of Low Frequency Neuromuscular Electrical Stimulation and Medium Frequency Neuromuscular Electrical Stimulation in Heart Failure, Heart Failure NYHA Class III and Heart Failure NYHA Class IV, sponsored by Universidade Federal do Rio Grande do Norte. Not yet recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-01.

Sponsored by Universidade Federal do Rio Grande do Norte · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Introduction: Heart failure (HF) is a clinical syndrome that has advanced on a large scale concomitant with population aging and other factors. Thus, the search for alternatives that minimize the losses resulting from its structural and functional damage are important to optimize its treatments, with the primary objective of enabling the participation of these individuals in the most diverse daily tasks. Low-frequency (LF) or medium-frequency (MF) neuromuscular electrical stimulation (NMES) can be considered a resource to enable the improvement of vital and functional parameters of the population with HF intolerant to physical exercise, and it is also important to identify within these modalities which is most effective. In addition to these factors, kinesiophobia can be found in this population, and NMES can also be adopted as a strategy for kinesiophobia in these patients, with the objective of enabling the progression of behaviors. Objective: To evaluate and compare the effectiveness of LF and MF NMES on the indices of kinesiophobia and functionality in patients with HF. Methods: The research will be divided into two types of study: a double-blind randomized clinical trial (RCT) to evaluate NMES protocols, and a qualitative study with subsequent development and validation of a questionnaire to measure kinesiophobia in individuals with HF. The population included in the RCT will have their assessments (personal, socioeconomic, demographic data, Sit-to-Stand Test, kinesiological ultrasound and surface electromyography of the quadriceps muscles) conducted before their discharge from Hospital Nova Esperança (HNE), and after completion of the protocols at the same institution, in the city of João Pessoa - Paraíba. The application of NMES protocols will be carried out in the home environment (30 min/day, 3 times a week, for a total of 8 consecutive weeks). The population for the qualitative study and for the development of the questionnaire will consist of individuals diagnosed with HF of any etiology, compensated and able to perform kinesiotherapy activities, admitted to the HNE wards, between 24-48 hours before hospital discharge. An in-depth semi-structured interview will be conducted with these individuals, followed by the application of questionnaires developed based on the interviews, and the entire study will be conducted while the patients are hospitalized. Expected results: Regarding the first study, it is expected that patients treated with NMES will show improvements in clinical and functional variables, and these improvements may be more pronounced depending on the frequency applied. On the other hand, the qualitative study may reveal whether patients have fear of movement, even if they are clinically stable. The developed questionnaire will be well understood and have adequate psychometric qualities. Finally, it is expected that this knowledge can serve as a basis for optimizing the care of this patient population.

Read the detailed description

Study 1 (double-blind randomized clinical trial) will be developed by recruiting individuals with chronic HF NYHA III-IV at the Hospital Nova Esperança (HNE), in the city of João Pessoa, state of Paraíba, Brazil, through advertising at the hospital where the participants' assessments will be performed (including patients who meet the study's eligibility criteria after hospital discharge). These individuals will be invited to participate in the study and instructed on its due procedures. To ensure the safety of the participants and reliability of the data, the medical records will be checked beforehand to ensure the necessary criteria are met. The researchers who will contribute to the study will be trained to perform the assessment of the participants, as well as to apply the LF and MF NMES protocol. The training will be offered by qualified professionals and the sequence and method of conducting the assessment and the NMES protocol will be recorded for the researchers involved. Strategies will be developed in advance to better organize the days, times, and logistics that seek to facilitate and optimize the conduct of the research, and will be planned according to the specificities of each researcher. Potential participants will be identified at the HNE together with the professionals of the service, who will maintain constant attention to identify patients who are eligible after their discharge. Once identified, they will contact the researchers to inform them, and the researcher responsible for this demand will go to the patient to provide explanations about the research, evaluate them, and ask for their telephone number to contact them after discharge. Other forms of recruitment will occur through active search in the aforementioned establishments and on social media. Randomization will be through the website randomization.com by a researcher who will not inform the evaluators, intervention researchers, or even the researcher who will perform the statistical analysis, about the groups in which these participants are located, leaving them blind. During randomization, participants will be allocated to three distinct groups: Intervention Group 1 (IG1): LF NMES protocol; Intervention Group 2 (IG2): MF NMES protocol; and Control Group (CG): NMES protocol without generation of muscle contractility. Four evaluators will participate in the study: researcher 1 will be responsible only for the evaluations, researchers 2 and 3 for the home application of the NMES protocols, and researcher 4 for randomization. The study will be double-blind, since researcher 1 and the participants will not be aware of the allocation of the subjects into the groups or the effects of the intervention. After the groups are formed, the research participants will be invited to come to the HNE outpatient clinic to perform the first day of evaluation before the start of the protocol. The evaluator will be a properly trained researcher who is blind to the intervention allocation group. This evaluation will include: personal, socioeconomic, and demographic data; collection of clinical data (history of the disease, ECHO results, and medications in use); vital signs (HR, RR, SpO2, and BP); lung, diaphragmatic, and quadriceps muscle ultrasound; lower limb perimeter; EMS of quadriceps muscles; 6MWT; application of the Lawton Scale and the Minnesota Living with Cardiac Insufficiency Questionnaire. After the day of the first assessment, the application of the GI1, GI2 and GC protocols will begin, which will occur for a total period of 8 weeks, 3 times/week, for 30 minutes on each day of application. The application days will be staggered, with a rest period between the scheduled days. The days and times will be assigned according to the availability of the participant and the researcher in charge. After 4 weeks of application of the protocol, they will return to the HNE outpatient clinic for a reassessment, which will have a specific day only for this purpose. After the reassessment, the application of the protocol will return. At the end of the 8 weeks, another reassessment will be performed, with the entire process being completed after 1 month of application of the protocol, with a follow-up.

In research number 2, for the process of constructing and validating the questionnaire, studies with different methodological designs will be carried out in two consecutive stages. The first stage will begin with the identification of the items that will make up the questionnaire. These items will be identified from a qualitative study with patients eligible for the research, through a semi-structured interview (which will be recorded for later analysis). The interview will be conducted with a guide of open-ended questions (between 3-5 questions) about the perceptions and/or concrete experiences of patients regarding their possible capabilities, fears or fear of performing physical activity. Participants will be recruited during their hospitalization, and their participation in the research will also occur during this same period. Immediately after this stage, the questionnaire items will be constructed, based on the main perceptions identified in the qualitative study and in the process of discussion and consensus of the researchers involved. The format of the questions and answers of the questionnaire will be defined after analysis of the qualitative data. Once the first version of the questionnaire is finalized, it will undergo a pre-test to assess the understanding of the items by the volunteers and health professionals of the service. Everyone will report their perception regarding the understanding and relevance of the questions. An item will undergo reformulation if less than 80% of those evaluated classify the term as incomprehensible or inadequate. The second stage, which corresponds to The validation of the questionnaire will also be performed with patients diagnosed with HF admitted to the service. The questionnaire will be given to the patients by the researcher, who will explain its purpose. Participants will have two days to return the completed questionnaire, to avoid recall bias. The informed consent form must be signed in duplicate by all participants. The test-retest reliability will be assessed by completing the questionnaire again, three days after the first, in a small sample of participants, approximately 30 subjects. Subsequently, the questionnaire will be applied to a representative sample of the hospital population to analyze its convergent and divergent validity, comparing it with other instruments and/or functional tests, such as the Anxiety and Depression Scale (HADS), Quality of Life (Minnesota Living with Cardiac Insufficiency), Exercise Tolerance (TSL1) and Surface Electromyography. Finally, clinical data will be extracted from the participants' medical records, as well as their length of hospital stay and the total period of care provided by the on-call physiotherapist to the participant being evaluated.

02

Conditions studied

  • Heart Failure
  • Heart Failure NYHA Class III
  • Heart Failure NYHA Class IV
  • Neuromuscular Electrical Stimulation (NMES)
  • Kinesiophobia

Keywords

  • heart failure
  • neuromuscular electrical stimulation
  • kinesiophobia
03

In context

Heart Failure

6,331 studies on the registry are indexed under Heart Failure; 1,396 are open to participants now.

This study's planned enrollment of 54 is below the median of 76 across 4,049 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Universidade Federal do Rio Grande do Norte is the lead sponsor of 86 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals of both sexes;
  • Age ≥ 18 years;
  • Diagnosis of chronic HF;
  • Symptoms compatible with Functional Class (FC) III-IV of the (NYHA);
  • Stable condition on pharmacological therapy;
  • Absence of Acute Myocardial Infarction in the last three months prior to participant recruitment;
  • Absence of an automatic internal cardioverter defibrillator (ICD) or cardiac pacemaker;

Exclusion criteria

Exclusion Criteria:

  • Individuals with hemodynamic instability, unstable angina, acute myocardial infarction during the period of application of the protocol and diagnosis of hypertrophic cardiomyopathy during the period of application of the protocol;
  • Individuals with recent muscle or tendon injuries, muscular dystrophies, myopathies, unstable fractures, infections or deep vein thrombosis (DVT);
  • Chronic need for oxygen therapy;
  • Absence in reassessments;
  • Refusal to participate in the research after its beginning.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
54 participants (estimated)

Study arms

  • Active comparator
    Low Frequency Neuromuscular Electrical Stimulation

    Participants in this group will undergo low-frequency neuromuscular electrostimulation interventions, in accordance with the adopted intervention protocol, with assessments before, after, and at the end of the protocol to observe its effects.

    Device: Low Frequency Neuromuscular Electrical Stimulation

  • Active comparator
    Medium Frequency Neuromuscular Electrical Stimulation

    Participants in this group will undergo medium-frequency neuromuscular electrostimulation interventions, in accordance with the adopted intervention protocol, with assessments before, after, and at the end of the protocol to observe its effects.

    Device: Medium Frequency Neuromuscular Electrical Stimulation

  • Placebo comparator
    Neuromuscular Electrical Stimulation without generating contractility

    Participants in this group will undergo neuromuscular electrostimulation interventions at a frequency below the contractility threshold, comprising the placebo group, in accordance with the intervention protocol adopted, with assessments before, after, and at the end of the protocol to observe its effects.

    Device: Neuromuscular Electrical Stimulation without generating contractility

Interventions

  • DeviceLow Frequency Neuromuscular Electrical Stimulation

    The surface electrodes will be placed on the upper lateral side of the quadriceps, 5 cm below the inguinal fold and 3 cm above the upper edge of the patella of both lower extremities, bilaterally and with a slight flexion of the knees. They will be fixed with bandages or tape, and conductive gel will be used below the electrodes. Each electrically stimulated contraction will have a frequency of 10 Hz, duration of 10 seconds (ON time: 10s), interspersed with a 20-second rest period (OFF time: 20s), with a pulse width of 400 µs. The protocol will last a total of 8 weeks, being performed 3 times a week, with application of the equipment for 30 minutes each day.

  • DeviceMedium Frequency Neuromuscular Electrical Stimulation

    The surface electrodes will be placed on the upper lateral side of the quadriceps, 5 cm below the inguinal fold and 3 cm above the upper edge of the patella of both lower extremities, bilaterally and with a slight flexion of the knees. They will be fixed with bandages or adhesive tape, and conductive gel will be used below the electrodes. Each electrically stimulated contraction will have a frequency of 50 Hz, duration of 10 seconds (ON time: 10s), interspersed by a period of 20 seconds of rest (OFF time: 20s), with a pulse width of 400 µs. The protocol will last a total of 8 weeks, being performed 3 times a week, with application of the equipment for 30 minutes each day.

  • DeviceNeuromuscular Electrical Stimulation without generating contractility

    The surface electrodes will be placed on the upper lateral side of the quadriceps, 5 cm below the inguinal fold and 3 cm above the upper edge of the patella of both lower extremities, bilaterally and with a slight flexion of the knees. They will be fixed with bandages or adhesive tape, and conductive gel will be used below the electrodes. No muscle contractions will be generated. The protocol will last a total of 8 weeks, being performed 3 times a week, with application of the equipment for 30 minutes each day.

06

What researchers measure

Primary outcomes

  1. Muscle strength

    A surface electromyograph (Miotool 400 - Miotec Equipamentos Biomédicos Ltda, POA, Brasil®) will be used to assess muscle production, strength and activation, calculating the maximum power that the patient will make in a voluntary isometric contraction of the quadriceps muscles (rectus femoris, vastus medialis and vastus lateralis), before and after the total NMES protocol.

    Time frame: In the initial assessment, four weeks after the start of the intervention, at the end of the intervention (eight weeks of intervention), and one month after the complete conclusion of the protocol.

  2. Muscle thickness

    Functional Kinesiological USG of the quadriceps muscles will be used to assess muscle thickness before starting the protocol, after 4 weeks and after the total intervention protocol with NMES, which may generate functional correlations with the protocol used. The evaluation protocol adopted will be that of Capmbell et al (1995) where quadriceps muscle thickness (QMT) will be quantified by a portable Mindray ultrasound, in B mode, in the supine position, with knees extended and relaxed.

    Time frame: At baseline, four weeks after the start of the intervention, at the end of the intervention (eight weeks of intervention), and one month after the complete conclusion of the protocol.

  3. Functional Capacity - 1-Minute Sit-to-Stand Test

    The individual is asked to sit and stand up in a standard-height chair (46-48 centimeters) positioned against a wall. The knees and hips should be flexed at 90 degrees, and the feet should be flat on the floor and hip-width apart. The patient's hands should rest on their hips and no support should be used. Over the course of one minute, the patient should sit and stand up from the chair repeatedly, aiming for as many times as possible. The test begins after a verbal command, and the patient will be notified when 15 seconds remain. The number of repetitions performed is counted and the modified Borg scale will be used to assess dyspnea and fatigue during and at the end of the test (BOHANNON \& CROUCH, 2018).

    Time frame: At baseline, four weeks after the start of the intervention, at the end of the intervention (eight full weeks of intervention), and one month after the complete conclusion of the protocol.

Secondary outcomes

  1. Participation in activities of daily living

    To assess the level of functional independence of research participants before, during and after the application of the protocol, the Lawton Scale will be used in the version translated and validated for the Portuguese language, which is a widely used instrument to assess individuals' participation in IADLs. The instrument consists of 7 items, each divided into three subitems, the main items being: telephone, travel, shopping, meal preparation, housework, medications and money. All items have three subitems, providing examples of specificities about the functional independence that the individual has when dealing with the points mentioned. The score ranges from 7 to 21.

    Time frame: At baseline, four weeks after the start of the intervention, at the end of the intervention (eight full weeks of intervention), and one month after the complete conclusion of the protocol.

  2. Quality of life of individuals with Heart Failure

    The Minnesota Living with Cardiac Insufficiency Questionnaire, translated and validated in Portuguese, will be used to assess QoL before, after 4 weeks of application of the protocol, after full application, and 1 month later by follow-up of NMES, with 21 objective questions that assess physical, emotional and socioeconomic conditions. It offers a scale ranging from 0 to 5, with a final score ranging from 0 to 10, where higher scores are associated with worse QoL.

    Time frame: At baseline, four weeks after the start of the intervention, at the end of the intervention (eight full weeks of intervention), and one month after the complete conclusion of the protocol.

07

Study locations

1 site
  • Av Capitão José Pessoa, 870, Jaguaribe
    João Pessoa, Paraíba 58015-345, Brazil
    • Micaele Farias Nascimento, Master's degree · Contactmicaele.farias@hotmail.com · 83987156995
    • Micaele Farias Nascimento, Master's degree · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that support the results of a publication will be shared.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: For the journal candidate for publication, from the transitional publication period, if necessary.

Access criteria: They will be available to the journal applying for publication of the article, if necessary, to ensure the reliability of the study, by email or contact indicated by the journal.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07099495
Lead sponsor
Universidade Federal do Rio Grande do Norte
Responsible party
Patri-cia Angelica de Miranda Silva Nogueira (Principal Investigator, Universidade Federal do Rio Grande do Norte) — Principal investigator
First posted
Aug 1, 2025
Start date
Aug 18, 2025 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Aug 1, 2025

Study contacts

Micaele Farias Farias Nascimento, Master's degree
Contact
micaele.farias@hotmail.com
+5583987156995
Patrícia A de Miranda Silva Nogueira, Doctorate degree (PhD)
Contact
idpa02@hotmail.com
+5584988777454
Patrícia A de Miranda Silva Nogueira, Doctorate degree (PhD)
study director · Universidade Federal do Rio Grande do Norte

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion